Onxeo to attend upcoming investor conferences and medical meetings
Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that senior management will present updates on the Company’s advanced orphan oncology pipeline at the following upcoming investor conferences:
- ODDO Biotech / Medtech Forum – March 31, 2016 in Paris (France)
- SFAF Journée Sectorielle Biotech – May 15, 2016 in Paris (France)
- Jefferies Healthcare Conference – June 7-10, 2016 in New York (U.S.A)
- European Large and Midcap Event – October 5-6, 2016 in Paris (France)
In addition, Onxeo will present at the following medical meetings:
- EASL, The International Liver Congress – April 13-17, 2016 in Barcelona (Spain)
- AACR Annual Meeting 2016 – April 16-20, 2016 in New Orleans (U.S.A)
- ESTRO Annual Meeting 2016 – April 29-May 3, 2016 in Turin (Italy)
Onxeo’s next financial updates will be released on the following dates:
- Full-Year 2015 Results – February 26, 2016 (after the close of market)
- Full-Year 2015 Results and Company Update Analyst Conference Call – February 29, 2016 (6:30 PM CET; dial-in details to be released beforehand)
- Annual SFAF Meeting – March 7, 2016 (11:00 AM CET) in Paris (France)
Investors and analysts interested in scheduling a meeting with Onxeo management or participating in a Company conference call can contact Onxeo’s Investor Relations team (investors@onxeo.com) or Lee Roth and Joseph Green at The Ruth Group (+1 646-536-7012/7013 or lroth@theruthgroup.com / jgreen@theruthgroup.com).